Amryt On Navigating Orphan Pricing And Reimbursement

 
• By Francesca Bruce

Rare and orphan disease company Amryt Pharma discusses where to launch first and how to convince payers to pay.

Pills
Amryt is aiming for prices that make a return on investment and which also reflect the value for patients

More from Pricing Debate

More from Market Access